MRM
SUPN icon

Michael R. Murphy’s Supernus Pharmaceuticals SUPN Stock Holding History

Michael R. Murphy’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-541,561
Closed -$8.26M – 19
2016
Q1 		$8.26M Sell
541,561
-378,989
-41% -$4.95M 2.88% 15
2015
Q4 		$12.4M Sell
920,550
-107,754
-10% -$1.67M 4.24% 12
2015
Q3 		$14.4M Sell
1,028,304
-846,923
-45% -$15.7M 4.96% 9
2015
Q2 		$31.8M Sell
1,875,227
-769,344
-29% -$11M 9.98% 1
2015
Q1 		$32M Sell
2,644,571
-451,018
-15% -$4.26M 12.32% 1
2014
Q4 		$25.7M Buy
3,095,589
+199,367
+7% +$1.68M 9.88% 5
2014
Q3 		$25.2M Buy
2,896,222
+389,876
+16% +$3.52M 8.71% 2
2014
Q2 		$27.4M Buy
2,506,346
+1,161,315
+86% +$10.3M 8.73% 2
2014
Q1 		$12M Buy
+1,345,031
New +$12.4M 3.56% 13

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Michael R. Murphy's SUPN Position: Q2 2016 in Review

Michael R. Murphy sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 541,561 shares — an estimated $8.26M sold.

Michael R. Murphy first reported a position in SUPN in Q1 2014 and held it in 9 quarters. The position peaked at $32M in Q1 2015. 214 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

  • Michael R. Murphy reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Michael R. Murphy sold 541,561 Supernus Pharmaceuticals shares in Q2 2016, an estimated $8.26M.
  • Michael R. Murphy first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 9 quarters.
  • Michael R. Murphy's Supernus Pharmaceuticals position peaked at $32M in Q1 2015.
  • 214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Michael R. Murphy's 13F filing for Q2 2016, filed 12 Aug 2016.